CD274 and neoplasm: Preclinical studies have demonstrated that aptamers targeting PD-L1 can achieve similar or even superior tumor growth inhibition in animal models in comparison to monoclonal antibodies (mAbs), with the added benefit of decreased immunogenicity [5].